From Fear to Confidence: DecisionDx-Melanoma. Greg’s Story of Empowerment Over a Melanoma Diagnosis
Discover Greg’s inspiring journey from a cancer diagnosis to a life of outdoor adventures, empowered by the DecisionDx-Melanoma test. Follow his path to knowledge and resilience in the face of melanoma.
Be Your Own Advocate: Morgan England, Stage III Melanoma Survivor, Shares Her Story
As a Stage III Melanoma survivor, Morgan speaks on how important it is to be your own advocate. After her diagnosis, she requested the DecisionDx-Melanoma test from her doctor for the additional information it can provide. The results she received from her DecisionDx-Melanoma test report continue to help reduce her anxiety and provide confidence about her future.
Castle Biosciences: Our Story
A closer look into Castle Biosciences: our 'why,' the mission driving our company, and the incredible people dedicated to improving patient care each and every day.
CDO - Highly Accurate & Objective Tests for Melanocytic Lesions of Uncertain Malignant Potential
DecisionDx®-Melanoma Helps to Guide Patient Management Decisions
Dr. Aaron Farberg speaks about how the DecisionDx-Melanoma test results helps better identify a patient's risk of metastasis and how some patients may be able to forgo a SLNB procedure.
DecisionDx®-Melanoma Increases the Risk Prediction that is Currently Available for Patients
Dr. Clay Cockerell speaks on how the DecisionDx-Melanoma test is not intended to replace staging systems but how using GEP can increase risk prediction for patients with Stage I-III melanoma.
Interview with Dr. Lucas C. Duits: Standardizing Patient Management with TissueCypher
This study evaluated the impact that variability in pathologic diagnosis has on patient care and shows that adding guidance from TissueCypher to the standard of care can improve the consistency of management and increase the percentage of progressors that receive appropriate treatment while reducing the number of non-progressors that are over treated.